Clinical Trial Update: AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating AK104 in combination with low-dose radiation for recurrent or metastatic head and neck squamous cell carcinoma after failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Fudan University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING